Clinical trials: Scleroderma
Systemic Sclerosis
Trial on Outpatients With Systemic Sclerosis Treated With Well-Being Therapy or With a Control Therapy
Systemic sclerosis (SSc) is a rare and potentially life-threatening autoimmune disorder with a significant impact on health and quality of life.
- Trial name
- NCT04212247
- Testing
- Well-Being Therapy, Control condition
- Where
- 2 sites in Italy
- Volunteers
- 60 people
- Sponsor
- University of Florence
Scleroderma, Systemic
Impact of Education and Training of Modified Rodnan Skin Scoring on the Reliability of Test
The aim of the study is evaluating the efficacy of organized education process of the modified Rodnan Skin Score (MRSS) in the systemic sclerosis.
- Trial name
- NCT03219606
- Testing
- Organized education course of Modified Rodnan Skin Scoring
- Where
- South Korea
- Volunteers
- 10 people
- Sponsor
- Seoul National University Hospital
Diffuse Cutaneous Systemic Sclerosis
A Study of Subcutaneous Abatacept to Treat Diffuse Cutaneous Systemic Sclerosis
The study hypothesis is that SC abatacept is safe and shows evidence of efficacy (improvement in modified Rodnan score [mRSS]) in patients with diffuse cutaneous systemic sclerosis (dcScc) compared to matching placebo.
- Trial name
- ASSET (NCT02161406)
- Testing
- Abatacept
- Where
- 27 sites in United States, Canada and 1 more
- Volunteers
- 88 people
- Sponsor
- Dinesh Khanna, MD, MS
Scleroderma, Systemic
The Benefit of Bermekimab in Patients With Systemic Sclerosis
This is a proof-of concept RCT trying to generate evidence that inhibition of IL-1α through the administration of bermekimab may inhibit progression of SSc.
- Trial name
- NCT04045743
- Testing
- MABp1 (Bermekimab)
- Where
- 2 sites in Greece
- Volunteers
- 20 people
- Sponsor
- Hellenic Institute for the Study of Sepsis
Interstitial Lung Disease
Patient-Reported Outcome Study of Project ECHO for ILD
The study will assess whether patients of providers participating in Project ECHO for ILD experience reduced stress, including financial stress, based on their ability to receive timely and local care and services, The study will…
- Trial name
- NCT05450276
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- Pulmonary Care and Research Collaborative Limited
Scleroderma
A Clinical Study on Systemic Sclerosis and the Validation of French-language Questionnaires Assessing Disability, Quality of Life, and Disease Status.
The main objective of this study is to validate, in French, new questionnaires assessing disability, quality of life, and patient-reported outcomes in systemic sclerosis.
- Trial name
- FRESS-VQ (NCT07888842)
- Testing
- Questionnaires
- Where
- France
- Volunteers
- 200 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Systemic Sclerosis
Evaluation of Aesthetic Impact in Patients With Systemic Sclerosis
The primary objective is to assess the burden of aesthetic complication in systemic sclerosis. Systemic sclerosis is associated with changes in skin aspect which can impact the appearance.
- Trial name
- SCLERO-ESTHET (NCT03271320)
- Testing
- appearance scales
- Where
- France
- Volunteers
- 170 people
- Sponsor
- University Hospital, Lille
Scleroderma, Scleroderma Associated Digital Ulcer
Co-designing Digital Ulcers Opportunities With Patients and Clinicians
Scleroderma (SSc) is a rare crippling chronic disease associated with damage of the blood vessels and hardening of connective tissue.
- Conditions
- Scleroderma, Scleroderma Associated Digital Ulcer, Digital Ulcer
- Trial name
- CoDUo (NCT05785403)
- Testing
- No intervention
- Volunteers
- 25 people
- Sponsor
- King's College London
Systemic Lupus Erythematosus, Cutaneous Lupus Erythematosus
A Study to Evaluate VIB7734 in Participants With Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus (CLE), Sjogren's Syndrome, Systemic Sclerosis, Polymyositis, and Dermatomyositis
The purpose of this study is to evaluate the safety and tolerability of escalating, multiple subcutaneous (SC) doses of VIB7734 in participants with Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus (CLE)…
- Conditions
- Systemic Lupus Erythematosus, Cutaneous Lupus Erythematosus, Sjogren's Syndrome, Systemic Sclerosis
- Trial name
- NCT03817424
- Testing
- VIB7734
- Where
- 30 sites in United States, Poland and 1 more
- Volunteers
- 31 people
- Sponsor
- Amgen
PHTN in Scleroderma Patients
Pulmonary Hypertension Screening in Scleroderma
Screening for pulmonary hypertension in scleroderma patients
- Trial name
- NCT07186439
- Volunteers
- 35 people
- Sponsor
- Assiut University
Systemic Lupus Erythematosus, Rheumatoid Arthritis
Early Clinical Study of UTAA91 Injection for the Treatment of Relapsed/Refractory Autoimmune Diseases
This clinical trial is designed as a single - arm, open - label, single - center, investigator - initiated early - phase clinical study.
- Conditions
- Systemic Lupus Erythematosus, Rheumatoid Arthritis, Dry Syndrome, Idiopathic Inflammatory Myopathies
- Trial name
- NCT06970951
- Testing
- UTAA91 injection
- Where
- China
- Volunteers
- 15 people
- Sponsor
- PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Interstitial Lung Disease With Systemic Sclerosis
Evaluation of Efficacy and Safety of Rituximab and Mycophenolate Mofetil Combination in Patients With Interstitial Lung Disease Related to Systemic Sclerosis
The goal of this clinical trial is to evaluate the efficacy on lung function after 24 weeks of rituximab + MMF combination comparatively to placebo + MMF combination in patients with SSc-ILD severe at the initial assessment or at…
- Trial name
- EVER-ILD 3 (NCT06549231)
- Testing
- Rituximab
- Where
- France
- Volunteers
- 102 people
- Sponsor
- University Hospital, Tours
Systemic Sclerosis Pulmonary, Pulmonary Hypertension
Infusion of Allogeneic Mesenchymal Stem Cells in Patients With Diffuse Cutaneous Systemic Sclerosis With Refractory Pulmonary Involvement
Progressive SSc is an entity with limited therapeutic alternatives and with asurvival rate of less than 45% in the first 3 to 5 years.
- Conditions
- Systemic Sclerosis Pulmonary, Pulmonary Hypertension, Pulmonary Fibrosis
- Trial name
- NCT04432545
- Testing
- Mesenchymal Stem Cells from Wharton ́s jellyintravenous infusion of Mesenchymal Stem Cells from Wharton ́s jelly
- Where
- Colombia
- Sponsor
- Universidad de la Sabana
Early and Severe Systemic Sclerosis
A Protocol Based Treatment for Early and Severe Systemic Sclerosis With (Anti-CD20), Rituximab
Rituximab 1000 mg i.v. will be given on day 1 and 15, week 26 - 28, together with a corticosteroid regimen consisting of methylprednisolone 100 mg i.v. 30 minutes prior to both infusions.
- Trial name
- NCT00379431
- Testing
- Administration of rituximab and methylprednisolone
- Where
- 4 sites in Belgium
- Volunteers
- 9 people
- Sponsor
- University Hospital, Ghent
Scleroderma
Taking Charge of Systemic Sclerosis
This Study is a collaborative project with partners (people with scleroderma and stakeholders) designed to refine an internet program for patients with scleroderma and to compare the internet program to an authoritative…
- Trial name
- TOSS (NCT02494401)
- Testing
- Internet-based self-management program, Scleroderma book
- Where
- United States
- Volunteers
- 267 people
- Sponsor
- University of Michigan
Rheumatoid Arthritis, Psoriatic Arthritis
Mindfulness Based Stress Reduction in Rheumatic Diseases
This study will assess the mental health and clinical benefits of Mindfulness Based Stress Reduction (MBSR) in patients with rheumatic disease who have anxiety or depression.
- Conditions
- Rheumatoid Arthritis, Psoriatic Arthritis, Scleroderma
- Trial name
- MBSR (NCT03411057)
- Testing
- Mindfulness Based Stress Reduction (MBSR), Control
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Johns Hopkins University
Healthy
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GS-248
This is a First in Human (FIH), double-blinded, parallel-group, randomised, placebo-controlled study designed to evaluate the safety, tolerability, PK and PD of single and multiple ascending oral doses of GS-248 in healthy…
- Trial name
- NCT04036227
- Testing
- GS-248
- Where
- Sweden
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Gesynta Pharma AB
Raynaud Phenomenon Secondary to Systemic Sclerosis
Efficacy of Botulinum Toxin A in Adult Subjects With Raynaud Phenomenon Secondary to Systemic Sclerosis
This study aims to assess whether or not a single injection schedule of botulinum toxin A (BTX-A) in both hands improves Raynaud phenomenon (RP) secondary to systemic sclerosis (SSc) better than a placebo at 4, 12 and 24 weeks…
- Trial name
- BRASS (NCT03717961)
- Testing
- BOTOX® solution
- Where
- France
- Volunteers
- 91 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Systemic Sclerosis
Effects of Intensive Aerobic and Muscle Endurance Exercise in Patients With Systemic Sclerosis - a Pilot Study
The hypothesis is that intensive aerobic and endurance muscle training is safe and beneficial in patients with systemic sclerosis and concurrent interstitial lung disease.
- Trial name
- NCT01813578
- Testing
- Exercise
- Where
- Sweden
- Volunteers
- 4 people
- Sponsor
- Karolinska University Hospital
Systemic Sclerosis, Deglutition Disorders
Swallowing Difficulties With Medication Intake and Coping Strategies in Patients With Systemic Sclerosis
The purpose of this study is the validation of a newly developed self-report questionnaire which aims at determining the prevalence, location and intensity of SWAllowing difficulties with drug intake, and describing the impact on…
- Conditions
- Systemic Sclerosis, Deglutition Disorders, Adherence to Medication Regime, Coping Behaviour
- Trial name
- SWAMECO (NCT02105818)
- Where
- Switzerland
- Volunteers
- 64 people
- Sponsor
- Kurt Hersberger